BlossomHill Therapeutics, Inc. BLSM
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 3.32M | 2.21M | 1.57M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 24.67M | 22.11M | 14.10M | ||
| Operating Income | -24.67M | -22.11M | -14.10M | ||
| Income Before Tax | -23.76M | -21.01M | -13.24M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -23.76M | -21.01M | -13.24M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -23.76M | -21.01M | -13.24M | ||
| EBIT | -24.67M | -22.11M | -14.10M | ||
| EBITDA | -24.55M | -21.98M | -14.00M | ||
| EPS Basic | -8.75 | -8.14 | -5.51 | ||
| Normalized Basic EPS | -5.47 | -5.09 | -3.44 | ||
| EPS Diluted | -8.75 | -8.14 | -5.51 | ||
| Normalized Diluted EPS | -5.47 | -5.09 | -3.44 | ||
| Average Basic Shares Outstanding | 2.71M | 2.58M | 2.41M | ||
| Average Diluted Shares Outstanding | 2.71M | 2.58M | 2.41M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||